Posted on

New Scientific Publication

Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet medical needs.

Beyond our oncology expertise, our innovative technological approach interfering with TSP-1/CD47 signaling may improve the lives of a large fraction of the (aging) population, such as people suffering from cardiovascular diseases.

Check out out pioneering results newly published in ATVB An American Heart Association Journal establishing Apmonia Tx’ asset as a new strategy of high therapeutic interest in controlling platelet activation and related thrombotic disorders, while being associated with a favorable safety profile and low bleeding risk.

#healthcare#biotech#cardiovasculardiseases#biotech

More :

https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.314571

Posted on

Business Angels Marne-Ardennes

We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)! 

This enables Apmonia Therapeutics to accelerate the development of its lead candidate AP-01 in solid tumors, while strengthening R&D team and increasing the company’s attractiveness towards industrial partners and investors.

#fightcancer#reims#bama#biotechnology

Posted on

Cancer Biology and Basic Sciences

We are thrilled to announce that Institut national du cancer (INCa) will provide financial support to a unique industry-academic R&D partnership gathering together Apmonia Therapeutics, MEDyC unit (CNRS UMR7369, Université de Reims Champagne-Ardenne, Prof. Stephane Dedieu, PI) and Gustave Roussy Cancer Center (INSERM U981, Dr. Alexandra Leary).

As part of the “Cancer Biology and Basic Sciences” 2020 call for proposals, our ambitious project aims at opening new therapeutic perspectives for the treatment of ovarian cancer, one of the highest unmet medical needs in oncology.

more :

https://www.e-cancer.fr/Institut-national-du-cancer/Appels-a-projets/Appels-a-projets-resultats/PLBIO-2020